Holen Sie sich die Stockscreener-App
45.09
0.60%
0.27
Handel nachbörslich:
45.50
0.41
+0.91%
Schlusskurs vom Vortag:
$44.82
Offen:
$44.82
24-Stunden-Volumen:
760.24K
Relative Volume:
0.60
Marktkapitalisierung:
$5.33B
Einnahmen:
$10.60M
Nettoeinkommen (Verlust:
$-252.45M
KGV:
-14.55
EPS:
-3.1
Netto-Cashflow:
$-158.91M
1W Leistung:
+1.17%
1M Leistung:
-4.67%
6M Leistung:
+70.47%
1J Leistung:
+724.31%
1-Tages-Spanne:
$43.39
$45.43
1-Wochen-Bereich:
$41.12
$45.59
52-Wochen-Spanne:
$5.15
$50.78
Avidity Biosciences Inc Stock (RNA) Company Profile
Firmenname
Avidity Biosciences Inc
Sektor
Branche
Telefon
858-401-7900
Adresse
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-24 | Eingeleitet | Goldman | Buy |
| 2024-08-28 | Eingeleitet | Barclays | Overweight |
| 2024-05-03 | Eingeleitet | BofA Securities | Buy |
| 2024-03-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-05-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Strong Buy |
| 2021-09-07 | Eingeleitet | Evercore ISI | Outperform |
| 2021-06-17 | Eingeleitet | Needham | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-07-07 | Eingeleitet | Cowen | Outperform |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-07-07 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-07 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Avidity Biosciences Inc Aktie (RNA) Neueste Nachrichten
Avidity Biosciences (NASDAQ:RNA) Trading 6.5% HigherShould You Buy? - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Avidity Biosciences Inc - GuruFocus.com
Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024 - PR Newswire
Avidity Biosciences' (RNA) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Avidity Biosciences advances FSHD therapy trial By Investing.com - Investing.com Canada
Avidity Biosciences target held at $59 by Goldman Sachs - Investing.com Canada
Chardan Capital Raises Avidity Biosciences (NASDAQ:RNA) Price Target to $65.00 - MarketBeat
Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Faciosca - StreetInsider.com
Avidity Biosciences advances FSHD therapy trial - Investing.com
Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy – Company Announce - Financial Times
Avidity Biosciences Announces Inducement Grants Under Nasdaq Lis - GuruFocus.com
Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Purchased by China Universal Asset Management Co. Ltd. - MarketBeat
Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors - StockTitan
Insider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Director Sells 5,000 Shares of Stock - MarketBeat
Avidity Biosciences director Levin sells $233k in stock By Investing.com - Investing.com UK
In-Depth Examination Of 10 Analyst Recommendations For Avidity Biosciences - Benzinga
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Financial Times
TD Cowen Boosts Avidity Biosciences (NASDAQ:RNA) Price Target to $78.00 - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Trading Down 5.2%What's Next? - MarketBeat
Moss Adams Wealth Advisors LLC Reduces Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Insider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells 25,000 Shares of Stock - MarketBeat
Avidity Biosciences chief HR officer McCarthy sells $1.21m in stock By Investing.com - Investing.com South Africa
Avidity Biosciences chief HR officer McCarthy sells $1.21m in stock - Investing.com
Avidity Biosciences Announces Expansion of Cardiovascular Collab - GuruFocus.com
Avidity Biosciences (NASDAQ:RNA) Hits New 1-Year HighWhat's Next? - MarketBeat
Avidity Biosciences stock soars to all-time high of $49.47 - Investing.com India
Avidity Biosciences stock soars to all-time high of $49.47 By Investing.com - Investing.com UK
Avidity Biosciences, Inc. (NASDAQ:RNA) Sees Large Increase in Short Interest - MarketBeat
SG Americas Securities LLC Has $582,000 Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences Receives FDA Orphan Drug Designation for AOC - GuruFocus.com
Avidity Biosciences, Inc. (NASDAQ:RNA) Stake Reduced by Millennium Management LLC - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Stock Price Down 5.5% on Insider Selling - MarketBeat
Avidity Biosciences director sells $1.35m in company stock By Investing.com - Investing.com South Africa
Avidity Biosciences director sells $1.35m in company stock - Investing.com India
Insider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Director Sells 30,000 Shares of Stock - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Stock Price Up 4.8%Should You Buy? - MarketBeat
Why Avidity Biosciences Zoomed to a 12% Gain This Week - MSN
Goldman Sachs Group (GS-N) QuotePress Release - The Globe and Mail
Avidity Biosciences shares buoyed by FDA lift on clinical hold - Investing.com Canada
FDA lifts hold on Avidity’s delpacibart etedesiran trial - The Pharma Letter
FDA lifts hold on Avidity Biosciences' DM1 drug trial By Investing.com - Investing.com South Africa
The Manufacturers Life Insurance Company Raises Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences' drug cleared by FDA By Investing.com - Investing.com South Africa
Avidity Biosciences' drug cleared by FDA - Investing.com
Avidity Biosciences: Good Prospects, But We Are A Little Late (RNA) - Seeking Alpha
Goldman Sachs maintains Buy rating on Avidity Biosciences shares By Investing.com - Investing.com UK
Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001) - GuruFocus.com
FDA lifts hold on Avidity Biosciences' DM1 drug trial - Investing.com
Finanzdaten der Avidity Biosciences Inc-Aktie (RNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):